Riskpilot← Back to searchSign inGet full accessNextCell Pharma AB
ABActiveOrg 5569658361Hälsovägen 7 8trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20145-9 employees
Revenue 2024
SEK 10,7M
+5% vs 2023
EBITDA margin
-395.7%
-4% vs 2023
Equity ratio
83.2%
Financial strength
Net profit 2024
SEK -42M
-5% vs 2023
| Revenue | SEK 10,7M | +5% |
| EBITDA | SEK -42,2M | -4% |
| Net profit | SEK -42M | -5% |
| Total assets | SEK 81,3M | -8% |
| Equity | SEK 67,6M | -11% |
| Employees | — | — |
Legal name
NextCell Pharma AB
Org number
5569658361
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19 mars 2014
Share capital
SEK 14 984 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att (i) driva vävnadsinrättningar, biobank och FOU-arbete med stamceller (ii) erbjuda tjänster för långtidsförvaring av stamceller (iii) löpande förvalta lös och fast egendom, samt därmed förenlig verksamhet.
Address
Hälsovägen 7 8tr
Email
info@nextcellpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 655 | 1 812 | 3 565 | 3 912 | 5 589 | 10 113 | 10 665 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −11 127 | −12 962 | −13 748 | −21 106 | −17 305 | 34 259 | −34 567 | −40 554 | −42 197 |
| Depreciation & amort. | −299 | −299 | −299 | −348 | −397 | −437 | −457 | −448 | −975 |
| EBIT | −11 426 | −13 261 | −14 047 | −21 454 | −17 702 | 33 822 | −35 024 | −41 002 | −43 172 |
| Net financials | 13 | 16 | 15 | 3 | 22 | 264 | 469 | 1 190 | 1 213 |
| Profit before tax | −11 413 | −13 245 | −14 032 | −21 451 | −17 681 | 0 | −34 554 | −39 812 | −41 960 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −11 413 | −13 245 | −14 032 | −21 451 | −17 681 | 34 086 | −34 554 | −39 812 | −41 960 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9 466 | 21 627 | 8 510 | 26 718 | 29 774 | 155 626 | 124 655 | 88 827 | 81 288 |
| Equity | 6 765 | 19 074 | 5 041 | 22 960 | 26 218 | 150 093 | 115 539 | 75 727 | 67 599 |
| Long-term debt | 703 | 696 | 761 | 940 | 1 381 | 1 576 | 2 185 | 3 020 | 3 816 |
| Short-term debt | 1 998 | 1 857 | 2 708 | 2 818 | 2 175 | 3 957 | 6 932 | 10 080 | 9 873 |
| Total debt | 2 701 | 2 553 | 3 469 | 3 758 | 3 556 | 5 533 | 9 117 | 13 100 | 13 689 |
EBITDA margin
-395.7%
This company
15.8%
Market median
-2604% vs market
20162024
Equity ratio
83.2%
This company
38.2%
Market median
+118% vs market
20162024
Return on equity
-62.1%
This company
18.4%
Market median
-438% vs market
20162024
Net profit margin
-393.4%
This company
8.1%
Market median
-4957% vs market
20162024
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20162024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MG Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
PJ Chief Auditor | Chief Auditor | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NextCell Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mathias Gösta Svahn | Chief Executive Officer | 0 companies |
| Per Johan Engstam | Chief Auditor | 0 companies |
| Camilla Myhre Sandberg | Board of Directors | 0 companies |
| Anders Essen-Möller | Chairman | 0 companies |
| Pingis Ingegerd Kristina Berg-Hadenius | Board of Directors | 0 companies |
| Leif Niclas Fredrik Löwgren | Board of Directors | 0 companies |
| Carl Inge Edvard Smith | Board of Directors | 0 companies |
| Hans Peter Torsten Ekre | Chairman | 0 companies |
| Eva Ulrika Saers | Board of Directors | 0 companies |